Scanfil (SCANFL) M&A announcement summary

Deal rationale and strategic fit

• Acquisition accelerates growth in Aerospace & Defense, targeting 40% of MB's turnover in 2025, and enhances presence in Southern Europe and Medtech & Life Science sectors.

• No overlapping customers, enabling cross-selling and portfolio diversification.

• MB brings a strong customer portfolio, with 40% of revenue from aerospace and defense, and offers access to new growth markets and customer segments.

• MB's four specialized sites in Southern Europe provide manufacturing capabilities and access to regional customers.

• The acquisition offers complementary competencies in electronics, certifications, and niche markets, supporting both organic and inorganic growth.

Financial terms and conditions

• The transaction values MB at a maximum enterprise value of €123 million, with €91 million paid upfront and up to €32 million contingent on 2026–2027 performance.

• Deal financed through existing credit facilities.

• MB reported €120 million in 2025 turnover, up 21.9% from 2024, with a comparable EBIT of €10.3 million and an EBIT margin of 8.6%.

Synergies and expected cost savings

• No customer overlap creates strong cross-selling opportunities and portfolio diversification.

• Opportunities identified to improve supply chain efficiency and leverage group scale.

• MB’s specialized certifications and competencies in Medtech and life science will enhance group offerings.

• Employee development and cross-company collaboration are expected to benefit both new and existing staff.